HiSiaddi is an innovative foreign trade service provider driven by dual pillars of technology transformation and foreign trade services, operating under the "1+2+3+4=1" service system with direct access to fumaric acid supplies from multiple well-known original manufacturers.
As a foreign trade enterprise with independent R&D capabilities, HiSiaddi frequently develops fumaric acid formulation optimization schemes and application improvement recommendations through technological transformation partnerships with manufacturers. Below is a case study of HiSiaddi’s fumaric acid formulation optimization consulting service.
Contact HiSiaddi customer service for further formulation optimization consulting support.
The buyer, MedNutra S.A. of Spain, is a leading manufacturer of mid-to-high-end nutritional formulations and pharmaceutical intermediates on the Iberian Peninsula, with over 20 years of expertise in premium European dietary supplements, pediatric chewable nutrition tablets, and ferrous fumarate APIs. Its products are sold in premium pharmacy chains and private medical institutions across Spain, Portugal, and France. All industrial products comply with six major access standards: European Pharmacopoeia (EP), United States Pharmacopeia (USP), EU E297 food additive specifications, German LFGB food safety standards, EU Regulation No. 1169 food labeling rules, and Kosher certification. As a typical refined high-volume purchaser, the enterprise rejects low-cost industrial-grade raw materials and benchmarks all procurement against the indicators of original European imported pharmaceutical-grade fumaric acid.
The company sourced fermented pharmaceutical-grade fumaric acid exclusively from BASF Germany for eight consecutive years. In 2025, European local chemical plant maintenance and skyrocketing natural gas raw material costs pushed import prices up by 32% with delivery cycles extended beyond 75 days. To optimize its global supply chain layout, the enterprise launched a local Chinese raw material replacement project with an annual target procurement volume of 156 tons of pharmaceutical fermented fumaric acid, split into two application categories: 28–36 mesh crystalline fumaric acid for sugar-free effervescent dietary tablets, and 130–150 mesh ultrafine fumaric acid for children’s chewable nutritional tablets and ferrous fumarate pharmaceutical intermediate synthesis.
After independently purchasing off-the-shelf products from two domestic fumaric acid mass manufacturers for the first time, the enterprise encountered three fatal mass production failures post-delivery: effervescent tablets cracking and gas expansion under high-temperature storage, gritty astringent mouthfeel in children’s chewable tablets, and excessive impurities detected via liquid chromatography in ferrous fumarate intermediates. Three production lines were forced into intermittent shutdown, delaying the new product launch schedule by nearly 45 days with over 1.2 tons of raw materials consumed for laboratory formulation testing, resulting in direct R&D and production halt losses. Manufacturers could only make minor adjustments to their standard mass-produced product parameters, lacking supporting technical expertise for pharmaceutical formulations and unable to implement two-way rectification covering both raw material and formulation sides. Recommended by the European Chemical Industry Council, the Spanish Procurement Director fully entrusted HiSiaddi’s foreign trade technical team with on-site fault investigation, root cause tracing, and delivery of a complete solution integrating raw material modification and formulation optimization.
HiSiaddi technical specialists conducted on-site inspections at the Spanish factory, cross-referencing workshop mass production data, accelerated stability test reports, and third-party physical and chemical testing reports to confirm all failures stemmed from three dimensions: excessive fumaric acid impurities, unreasonable particle size distribution, and mismatched physical and chemical properties between raw materials and formulations. Each failure manifestation and production hazard was analyzed item by item.
1. Excessive by-product maleic acid causing unqualified intermediates: Ultrafine fumaric acid used for ferrous fumarate synthesis tested at 0.038% maleic acid upon arrival, far exceeding the client’s internal control limit of ≤0.012%. Maleic acid, a cis-structured impurity, generates uncontrollable secondary salts during high-temperature chelation reactions, creating abnormal peaks in intermediate liquid chromatography testing that fail EU pharmaceutical authority incoming raw material inspections and render entire batches of intermediates scrapped. Traceability confirmed domestic off-the-shelf products adopted a simple single crystallization process lacking ion exchange impurity removal in fermentation refining, with mass production prioritizing cost reduction without deep refining for pharmaceutical applications.
2. Polarized particle size distribution triggering effervescent tablet gas expansion and cracking: Raw materials for 28–36 mesh effervescent products contained over 32% fine powder and 18% oversized particles. With a fixed acid-base ratio of fumaric acid and sodium bicarbonate in the effervescent formula, fine particles feature a large specific surface area and undergo slow premature moisture absorption reactions with the alkali source, causing internal gas generation and packaging swelling after 30 days of sealed storage. Oversized particles dissolve slowly, leaving solid residues at the bottom of liquid mixtures and resulting in turbid effervescent solutions failing finished product quality control standards. Original domestic manufacturers lacked graded screening production lines, packaging finished goods directly without narrow-range particle size control.
3. Poor ultrafine powder fluidity leading to rough chewable tablet texture: 140-mesh ultrafine fumaric acid exhibited high static electricity and minor agglomeration, causing frequent bridging and blockages in automatic batching feeding hoppers that required production line shutdowns every two hours to clean pipelines. A wide particle size span with residual coarse grains created strong gritty sensations during children’s tablet consumption, with sensory evaluation pass rates below 60% and non-compliance with European infant food texture specifications. Simultaneously, raw material moisture content of 0.31% exceeded standards; high-temperature and high-humidity summer conditions in the Mediterranean accelerated raw material moisture absorption and agglomeration during storage, exacerbating production failures.
Beyond inherent raw material defects, the client’s original formulations were fully designed around the physical and chemical parameters of original German fumaric acid. Failure to adjust acid-base ratios and granulation processes after switching to domestic raw materials amplified production defects caused by raw material flaws, creating composite failures stemming from mismatched raw materials and formulations.
HiSiaddi assembled a three-person special task force including organic acid process engineers, pharmaceutical formulation specialists, and quality control compliance officers. Rectification was split into three parallel phases: upstream raw material production process targeted technical renovation, downstream end-product formulation optimization, and packaging & storage improvement. While coordinating domestic manufacturers to optimize raw materials via technical transformation, formulation parameters were fine-tuned on-site at the Spanish factory to shorten rectification cycles through synchronous two-way progress.
HiSiaddi selected compliant leading domestic manufacturers specializing in biologically fermented fumaric acid, coordinating dedicated clean isolated production lines segregated from industrial and synthetic-grade fumaric acid to prevent cross-contamination and optimizing full-process production technology.
1. Impurity control optimization: Optimized constant-temperature cultivation parameters for fermentation strains to lower baseline maleic acid generation during fermentation; replaced the original single crystallization process with two-stage ion exchange resin impurity removal plus low-temperature activated carbon adsorption processes, followed by secondary negative-pressure recrystallization to remove heavy metals, coking impurities, and residual solvents. Finished product testing recorded maleic acid at 0.008%, heavy metals (lead, arsenic, cadmium) <0.35ppm, ignition residue ≤0.009%, all outperforming the client’s internal control thresholds and meeting EP Pharmacopoeia limits.
2. Dual-specification customized particle size transformation: For effervescent tablet raw materials, stepped slow cooling crystal growth technology was adopted to precisely produce uniform compact crystals of 28–36 mesh, restricting particles outside the target range to less than 5% of total volume. For chewable tablet ultrafine powder, closed low-temperature airflow pulverization plus three-stage graded screening removed coarse particles, with ≥93% of finished powder falling within the 130–150 mesh range. A simultaneous vacuum low-temperature drying process locked raw material moisture below 0.10%, eliminating hidden risks of powder moisture absorption and agglomeration.
3. Raw material traceability control: Locked designated non-GMO corn saccharification liquid for fermentation raw materials and established full-batch traceability ledgers covering raw material warehousing → fermentation production → refining crystallization → finished product delivery, with supporting raw material source documentation per batch to meet EU organic raw material traceability audit requirements.
Based on on-site measured data from formulation engineers, ratios and production processes were fine-tuned without altering the client’s core formulation framework or replacing other auxiliary materials to resolve mass production defects for both effervescent and chewable tablet categories.
1. Sugar-free effervescent dietary tablet optimization: The original acid-base ratio of fumaric acid to sodium bicarbonate of 1:1.22 was adjusted to 1:1.18 due to slightly elevated effective acid value of refined domestic fumaric acid. Separate dry granulation of acid and alkali particles was implemented, with mixing conducted immediately prior to tableting after separate storage to avoid premature moisture absorption and gas generation. An additional 0.4% pharmaceutical anhydrous lactose was added to the formula to improve particle fluidity, completely eliminating tablet cracking during storage.
2. Children’s chewable nutritional tablet optimization: A small quantity of microcrystalline cellulose was pre-mixed with ultrafine fumaric acid to improve powder anti-static performance and eliminate blockages during automatic feeding. Sweetener ratios were fine-tuned to mask subtle sourness; combined with homogeneous screened fine powder, gritty chew sensations were fully eliminated, lifting sensory inspection pass rates above 99%.
3. Ferrous fumarate intermediate optimization: Chelation reaction temperature and pH control points were adjusted according to raw material impurity data to reduce secondary by-product generation, eliminating abnormal peaks in intermediate liquid chromatography testing and enabling one-time passing of Spanish pharmaceutical authority incoming raw material audits.
Original standard PE-lined woven bags lacked sufficient moisture resistance, accelerating raw material deterioration through moisture absorption under Mediterranean high-temperature and high-humidity conditions. HiSiaddi coordinated packaging manufacturers to produce customized high-barrier aluminum-plastic composite vacuum inner bags paired with thick kraft outer bags. Bag surfaces were printed with Spanish-English bilingual markings including E297 code, CAS number, batch information, and allergen declarations to comply with EU Regulation No. 1169 labeling rules. Simultaneously, storage control specifications were provided to the client, mandating raw material storage at a constant temperature of 22°C with ambient humidity ≤53%, and immediate secondary vacuum sealing of partially unpacked raw materials to eliminate storage moisture absorption risks.
Samples were delivered in three progressive batches: 500g laboratory samples → 50kg workshop pilot materials → 1.2-ton mass production trial cargo.
· Round 1 laboratory compatibility testing of small samples fully passed all indicators;
· 50kg pilot raw materials completed full-process mass production at the Spanish factory, with effervescent tablets showing no gas expansion or cracking after 6 months of room-temperature accelerated testing, chewable tablets passing all sensory and dissolution standards, and ferrous fumarate intermediates clearing one-time testing;
· Zero production line shutdown failures were recorded during full-process manufacturing with 1.2-ton trial bulk goods, down from an average of three daily shutdowns previously.
The client formally signed an annual framework procurement contract for 156 tons: 87 tons of 28–36 mesh crystalline raw materials for effervescent tablets, and 69 tons of 130–150 mesh ultrafine raw materials for chewable tablets and intermediates. Goods were shipped monthly in 11 staggered batches. The first container departed Shanghai Port for Valencia Port, Spain, complete with Spanish-English bilingual CoA test reports, CNAS inspection certificates, GHS English SDS, and Kosher certificates, enabling one-time customs clearance. The client’s three suspended production lines resumed full-capacity manufacturing, and three new products previously delayed for launch entered premium nutritional product markets across the Iberian Peninsula as scheduled.
In the following year of cooperation, the client expanded OEM businesses in Morocco and Portugal via stable localized Chinese raw material supply, placing an additional customized pharmaceutical-grade fumaric acid order of 42 tons. All organic acid raw material procurement and technical debugging work were fully entrusted to HiSiaddi.
1. Raw material modification paired with two-way formulation optimization enabled successful localization replacement of German imported fumaric acid, cutting comprehensive procurement costs by 28.3% and eliminating supply chain risks including European raw material price surges and uncontrollable delivery lead times;
2. Long-standing production line shutdown and finished product scrapping failures were fully resolved, recovering economic losses from prior production halts and raw material waste, enabling timely new product launches to capture market windows for Southern Europe’s premium nutritional products;
3. Leveraging raw material internal control standards and formulation adaptation databases compiled by HiSiaddi, a full incoming raw material inspection specification for fumaric acid was established, shortening new product formulation R&D cycles by 52% and drastically reducing losses from discarded R&D samples.
Supported by this benchmark European high-end order, manufacturers completed technical upgrades for pharmaceutical-grade refined production lines and improved EP Pharmacopoeia-compliant quality control systems and graded screening processes, escaping low-price homogenized competition in industrial-grade fumaric acid. With this successful Spanish implementation case, they successively secured designated supply qualifications for three premium nutritional product enterprises in France and Greece, with export volumes of pharmaceutical-grade products rising from an initial 11% to 37% of total output.
Transcended the crude trading model centered solely on spot product profit margins, establishing technological service barriers integrating raw material process technical renovation, formulation optimization for end pharmaceuticals, packaging & storage supporting services, and full EU compliance documentation. Professional technical expertise enabled deep binding with mid-to-high-end pharmaceutical and dietary clients across Western Europe. A database covering fumaric acid compatibility with different dosage forms was established, supporting subsequent delivery of technical supporting procurement projects for four comparable high-end pharmaceutical enterprises in Italy and the Netherlands, continuously expanding the enterprise’s pool of refined chemical raw material clients in Europe.
The majority of domestic fumaric acid manufacturers prioritize capacity deployment for standard food-grade and petrochemical synthetic industrial-grade products, with crystallization and screening equipment designed for low-cost mass production. Production focus centers on capacity expansion and price compression, lacking capabilities for refined deep purification and narrow-range particle size grading required for European and American Pharmacopoeia-grade products. Production technical staff are only familiar with chemical synthesis processes and lack understanding of formulation logic for downstream tablets and intermediates. Meanwhile, mid-to-high-end pharmaceutical and dietary enterprises in Europe and America are bound by strict EP Pharmacopoeia and EU food additive regulations; minor deviations in fumaric acid trace impurities, particle size, or acid value trigger cascading failures including mass production scrapping and failed pharmaceutical authority inspections of finished goods. Formulations are historically designed around parameters of original European imported raw materials, and enterprises lack professional institutions to coordinate two-way rectification after switching to domestic raw materials, easily leading to mass production failures.
As an independent third-party foreign trade technical service provider, HiSiaddi bridges technological disparities between China and overseas markets. It coordinates upstream manufacturers to deliver customized technical renovation and optimize raw material physical and chemical indicators on one hand, while conducting fine-tuning of end-product pharmaceutical formulations on-site at downstream overseas factories on the other, breaking compatibility barriers between domestic raw materials and overseas end-product formulations. This case clearly demonstrates the core development direction of refined chemical foreign trade: transitioning from simple commodity sales to technology-empowered full-chain services. It not only supports overseas mid-to-high-end clients in completing supply chain localization and cost reduction upgrades but also assists high-quality domestic fermented fumaric acid in escaping low-end homogenized competition and steadily penetrating Europe’s premium pharmaceutical raw material blue ocean market, delivering a replicable technical implementation model for mid-to-high-end exports of China’s organic acid industry.
Contact HiSiaddi customer service for further formulation optimization consulting support.
+86-13120989737 
info@hisiaddi.com 
English
